[PDF] Plant-based Vaccines Market Continues to Expand Effective Alternative to Conventional Vaccines
Various studies are being conducted on plant-based vaccines as a cheap alternative to the conventional vaccine in terms of efficiency, production time, and immune system. The market players, and rising number of start-ups and research institutes are focused on R&D activities to develop treatment therapies for various infectious disease indications such as flu, dengue, norovirus, and avian influenza H5N1; based on new plant-based source vaccine. For instance, in August 2018, researchers from Arizona State University’s (ASU) Biodesign Institute developed a norovirus vaccine from tobacco plant. Genetic engineering allowed researchers to transfer specific genes from tobacco plant in designing plant-based vaccine for norovirus. Plant-based vaccine is safe and effective for use against various infectious diseases, as it activates patient’s immune system. In June 2018, researchers from the University of Nottingham, Malaysia, announced a project to develop plant-based vaccine for treatment of dengue fever caused by Aedes genus mosquitoes.
Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.coherentmarketinsights.com/insight/request-sample/2004
By using tobacco plant, researchers were successful in producing vaccine antigen that has the capability to neutralize dengue virus. Moreover, vaccines produced through plant sources provide a new platform to produce vaccines that can be orally administered rather than intravenously, which is the route of administration for most of the currently available vaccines. Researchers are also conducting research on edible plant species such as lettuce for production of vaccines in the near future. Successful completion of research studies are expected to help in developing safe and cost effective treatment to prevent dengue. For instance, according to the Journal of Botany: March 2016, the dengue virus vaccine targeting dengue-3 serotype polyprotein (DENV3prM/E) was produced in Lactuca sativa (lettuce) through a chloroplast transformation. It is further concluded that lettuce is an excellent host for agroinfiltration with deconstructed viral vectors.
Major players operating in the global plant-based vaccines market are adopting inorganic growth strategies such as collaboration and acquisition to expand their R&D capabilities in development of new plant-based vaccines. For instance, in June 2016, The Texas A&M University System (including Texas A & M University AgriLife Research and the Texas A & M Institute of Infectious Animal Diseases (IIAD)) entered into an agreement with iBio, Inc. and its subsidiary, iBio CMO LLC, for a collaborative program in plant-produced pharmaceuticals. This collaboration is expected to leverage R&D resources of the research institute with the commercial therapeutics and vaccine development, and manufacturing capabilities of iBio. Through this collaboration, their objective was to rapidly develop and test cost-effective, commercial, therapeutic, and vaccine solutions against various diseases such as influenza and Ebola.
Furthermore, in July 2013, Medicago, Inc., a Canada-based biopharmaceutical company, entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation, whereby Medicago was acquired by Mitsubishi with 60% share in Medicago, Inc. 40% of the shares are currently held by Philip Morris Investments B.V.
Request Here For PDF Brochure:
By Vaccine Type:
- Bacterial Vaccines
- Viral Vaccines
- Parasite Vaccines
- Others Vaccines
- Tobacco Plant
- Others Sources
- Zika Virus Disease
- Ebola Virus Disease
- Poultry Diseases
- Others Applications
If opting for the Global version of Plant-Based Vaccines Market analysis is provided for major regions as follows:
North America (The US, Canada, and Mexico)
Europe (the UK, Germany, France, and Rest of Europe)
Asia Pacific (China, India, and Rest of Asia Pacific)
Latin America (Brazil and Rest of Latin America)
Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)
Buy This Complete A Business Report With Flat US $2000 Off @
Key Takeaways of the Global Plant-based Vaccines Market:
- The global plant-based vaccines market is expected to exhibit a CAGR of 49.9% over the forecast period. This is attributed to rising number of R&D activities by key players to develop plant-based vaccines through novel sources.
- Among vaccine type, viral vaccines segment is expected to hold largest share in the market over the forecast period. Plant-based viral vaccines have been studied against Hepatitis B virus, Hepatitis C virus, Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), influenza virus, Bluetongue Virus (BTV), and rabies virus.
- Among source, the tobacco plant segment is expected to hold largest market share in 2020 and is expected to retain its dominance over the forecast period. In the manufacturing of plant-based vaccines, tobacco plant is mostly the preferred plant source. It is also being studied to develop vaccines for the treatment of diseases such as norovirus, Zika virus, polio, and influenza.
- Among application, the influenza segment is expected to hold largest market revenue and market share during the forecast period (2020-2026). Among influenza patients, plant-based vaccine is largely used in patients suffering from seasonal influenza. The infection caused due to influenza can be significantly reduced by using plant-based vaccines.
Some of the major players operating in the global plant-based vaccines market include Medicago, Inc., IBIO, Inc., Icon Genetics GmbH, Lumen Bioscience, Inc., British American Tobacco Plc., Creative Biolabs, Inc., Leaf Expression Systems Ltd., ZYUS Life Sciences Inc., PlantForm Corporation, and Infectious Disease Research Institute (IDRI)
Table of Content
Global Plant-Based Vaccines Market Research Report
Section 1: Global Plant-Based Vaccines Industry Overview
Section 2: Global Economic Impact on Plant-Based Vaccines Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Plant-Based Vaccines Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2004
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire